Synthesis and anticonvulsant evaluation of some new 2-substituted-3- arylpyrido[2,3-d]pyrimidinones

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 21, 2004, Pages 5711-5717

  White, David C ^a   Greenwood, Thomas D ^a   Downey, Aaron L ^a   Bloomquist, Jeffrey R ^b   Wolfe, James F ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b Division of Biomedical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; PYRIMIDINONE DERIVATIVE; SODIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; ELECTRIC SHOCK; MOUSE; NONHUMAN;

ANIMALS; ANTICONVULSANTS; DRUG EVALUATION, PRECLINICAL; MALE; MICE; MICE, INBRED ICR; PYRIMIDINONES; RATS; SEIZURES;

MURINAE;

EID: 4644337416     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.07.068     Document Type: Article

References (20)

1. (a) Von K.-H. Boltze, H.-D. Dell, H. Lehwald, D. Lorenz, and M. Räberg-Schweer Arzneimittel-Forsch 13 1963 688
2. (b) E. Kretzschmar Pharmazie 35 1980 253
3. M. Ionescu-Pioggia, M. Bird, M.H. Orzack, F. Benes, B. Beake, and J.O. Cole Int. Clin. Psychopharmacol. 3 1988 97
4. See J.M. Witkin, J.L. Katz, and J.E. Barrett J. Pharmacol. Exp. Ther. 218 1981 1 and references cited therein
5. J.F. Wolfe, T.L. Rathman, M.C. Sleevi, J.A. Campbell, and T.D. Greenwood J. Med. Chem. 33 1990 161
6. 1H NMR and X-ray crystallographic data, see: N.E.C. Duke, and P.W. Codding Acta. Cryst. B49 1993 719
7. N.A. Vaidya, C.H. Panos, A. Kite, W.B. Iturrian, and C.D. Blanton J. Med. Chem. 26 1983 1422
8. W.M. Welch, F.E. Ewing, J. Huang, F.S. Menniti, M.J. Pagnozzi, K. Kelly, P.A. Seymour, V. Guanowsky, S. Guhan, M.R. Guinn, D. Critchett, J. Lazzaro, A.H. Ganong, K.M. DeVries, T.L. Staigers, and B.L. Chenard Bioorg. Med. Chem. Lett. 11 2001 177
9. 50 of 1.5 mg/kg
10. F.R. Preuss, and E. Hoffmann Dtsch. Apoth. Ztg. 116 1976 893
11. Anticonvulsant Screening Project, Antiepileptic Drug Development Program; National Institutes of Health, DHEW Publ (NIH) (US), 1978; pp 78-1093
12. R.L. Krall, J.K. Penry, B.G. White, H.J. Kupferberg, and E.A. Swinyard Epilepsia 19 1978 409
13. R.J. Porter, J.J. Cereghino, G.D. Gladding, B.J. Hessie, H.J. Kupferberg, B. Scotville, and B.G. White Cleveland Clin. Q. 51 1984 293
14. Swinyard, E. A.; Wolf, H. H.; Franklin, M. R.; Chweh, A. Y.; Woodhead, J. H.; Kupferberg, H. J.; Gladding, G. D. Technical Report for 79146 on Contract No. N01-N5-4-2361; Epilepsy Branch, National Institute of Neurological and Communicative Disorders and Stroke: Bethesda, MD, 1984
15. J.R. Bloomquist, and D.M. Soderlund Biochem. Biophys. Res. Commun. 133 1985 37
16. 50 for 2a could not be determined due to limited solubility, which precluded testing at concentrations >200 μM
17. M.L. Kirby, R.L. Barlow, and J.R. Bloomquist Toxicol. Sci. 61 2001 100
18. B.L. Chenard, F.S. Menniti, M.J. Pagnozzi, K.D. Shenk, F.E. Ewing, and W.M. Welch Bioorg. Med. Chem. Lett. 10 2000 1203
19. M.G. Kassem, and F.S.G. Soliman Monatsh. Chem. 114 1983 1197
20. M.S. Reddy, and C.V. Ratnam Indian J. Chem. 23B 1984 977